相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer
Jie Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Metastatic Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA
Mario Eisenberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
Stephane Oudard et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)aEuro
M. Joerger et al.
ANNALS OF ONCOLOGY (2016)
Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel
Stefanie Kraff et al.
THERAPEUTIC DRUG MONITORING (2015)
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
Axel Heidenreich et al.
EUROPEAN JOURNAL OF CANCER (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
Geraldine M. Ferron et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study
V. Dieras et al.
EUROPEAN JOURNAL OF CANCER (2013)
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding
Peter de Bruijn et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study
C. Villanueva et al.
EUROPEAN JOURNAL OF CANCER (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2009)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioning
TR Glass et al.
JOURNAL OF UROLOGY (2003)
分享论文
